Fourth-Quarter and Full-Year 2019 Orphan and Rheumatology Segment Results
Fourth-Quarter and Full-Year 2019 Orphan and Rheumatology Segment Results
Driven by Strong KRYSTEXXA Growth
($M)
KRYSTEXXAⓇ
RAVICTIⓇ(1)
PROCYSBIⓇ
ACTIMMUNE®
RAYOS®
BUPHENYLⓇ(1)
QUINSAIR™
LODOTRA®(1)
Orphan and rheumatology segment net sales
Q4 2019
Q4 2018
% Change
FY 2019
FY 2018
% Change
$110.7
$83.3
33
$342.4
$258.9
32
32
68.5
60.2
14
228.8
226.6
1
40.8
40.1
2
161.9
154.9
5
28.4
27.5
3
107.3
105.6
2
19.5
19.8
78.6
61.1
29
1.6
6.4
(75)
9.8
21.8
(55)
0.3
0.2
68
0.8
0.5
62
0.1
NM
2.1
NM
$269.8
$237.6
14
$929.6
$831.5
12
Orphan and rheumatology segment operating income
$95.4
$84.8
13
$306.3
$290.0
6
NM: Not meaningful.
(1) Beginning in 2019, the Company no longer recognizes revenue from RAVICTI and AMMONAPS sales outside of North America and Japan, nor from sales of LODOTRA. On Dec. 28, 2018, the Company divested the rights to RAVICTI and AMMONAPS outside
of North America and Japan. AMMONAPS is known as BUPHENYL in the United States. In addition, effective Jan. 1, 2019, the Company transferred the rights to LODOTRA to Vectura Group plc. LODOTRA is known as RAYOS in the United States.
HORIZON
41View entire presentation